ReviewDrugs2014
Omalizumab for severe asthma: efficacy beyond the atopic patient?
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- Review
- Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients.International journal of molecular sciences · 2025Article
- The Incredible Adventure of Omalizumab.International journal of molecular sciences · 2024Review
- Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.Pharmaceutics · 2023Article
- From the Allergic Cascade to the Epithelium-Driven Disease: The Long Road of Bronchial Asthma.International journal of molecular sciences · 2023Article
- 2021 Brazilian Thoracic Association recommendations for the management of severe asthma.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Review
- Dual Monoclonal Antibody Therapy for a Severe Asthma Patient.Frontiers in pharmacology · 2020Article
- The prostaglandin DRespiratory research · 2018Review
- Omalizumab for Severe Asthma: Beyond Allergic Asthma.BioMed research international · 2018Review
- Role of IL-15 in the modulation of TGF-β1-mediated inflammation in asthma.Experimental and therapeutic medicine · 2017Article
- Review
- dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.International journal of molecular sciences · 2017Review
- Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.International journal of molecular sciences · 2017Article
- Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen-induced allergic rhinitis.British journal of pharmacology · 2016Article
- A review of omalizumab for the management of severe asthma.Drug design, development and therapy · 2016Review
- The asthma COPD overlap syndrome (ACOS).Current allergy and asthma reports · 2015Review
- Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit.Drugs · 2014Article
- [Consensus document for severe asthma in adults. 2022 update].Open respiratory archivesArticle
- Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.Therapeutic advances in respiratory diseaseReview
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several years ago, omalizumab became commercially available for the treatment of severe asthma. It remains the only monoclonal antibody to be marketed for this purpose. Since then, many studies have been published endorsing its efficacy and effectiveness. Concomitantly, evidence of an overlap between atopic and non-atopic severe asthma has emerged. However, there also appears to be some disagreement regarding the value of omalizumab in the management of non-atopic disease, as some studies have failed to show any benefit in these patients. The recent literature has also sought to identify appropriate prognostic biomarkers for the use of omalizumab, other than immunoglobulin (IgE) levels. This article briefly summarizes the evolution of asthma treatment, the pathophysiology of the condition, and the method of action of omalizumab. The author describes the controlled and uncontrolled studies (also named "real-life studies") published in adult and pediatric populations in different countries and expresses his view on the current place of the drug in the management of severe allergic asthma. He offers a personal perspective on the recent evidence for the use of omalizumab in non-atopic patients, highlighting the implications for current clinical practice and the gaps in our knowledge. The author justifies his belief that omalizumab is not only an IgE-blocking drug and should be considered as a disease-modifying therapy because of its multiple effects on different biologic pathways. Finally, some areas for future research are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.